Healthcare Global Enterprises share price today

Healthcare Global Enterprises Ltd's share price was ₹621.35 at the close on 4 November 2026. It has been rising for 20 weeks. That is 2.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between ₹528 and ₹755, and at that close it sat 41% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Healthcare Global Enterprises Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 5 weeks running.

Over the last 11 years the share price moved +257% while the NIFTY 500 moved +243%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 1 October 2026. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), profit grew again in the June 2026 quarter and foreign funds (FIIs) cut their stake for 4 quarters in a row.

1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹695 crore, +13.4% on a year earlier.

   Why: More patients came and the company earned more from people outside low margin government schemes. Many hospitals had their best ever quarter.

   Next results: check whether existing hospitals keep growing at the planned pace and new beds start earning.

   From the earnings call on 7 Aug 2026.

2. Profit grew again in the June 2026 quarter

   Profit was ₹16 crore, +166.7% on a year earlier (₹6 crore), after 2 quarters of decline.

   Why: Profit rose because dropping some low margin chemotherapy lifted the company's margin, so more of each rupee of sales became profit.

   From the earnings call on 7 Aug 2026.

3. Foreign funds (FIIs) cut their stake for 4 quarters in a row

   From 3.6% to 2.7% of the company by the September 2026 quarter.

For April to June 2026 (the quarter ended 30 June 2026), Healthcare Global Enterprises reported revenue of ₹695 crore, up 13.4% from ₹613 crore a year earlier, and a profit of ₹16.0 crore, up 166.7% from ₹6.00 crore.

Healthcare Global Enterprises results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Healthcare Global Enterprises' management discussed these results on a call held on 7 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Healthcare Global Enterprises closed at ₹621.35 on 4 November 2026, down 17.7% from ₹754.93 a year earlier (7 November 2025) and up 159.0% over five years. Its highest weekly close since April 2016 was ₹754.93 on 7 November 2025.

Healthcare Global Enterprises share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

560 weekly closes from 1 April 2016 to 4 November 2026.

4 Nov 2026: Healthcare Global Enterprises closed at ₹621.35, up 6.1% on the week and down 7.1% on the month. 7 Aug 2026: Healthcare Global Enterprises held its results call for April to June 2026. Management guided: Mid-teens revenue growth from existing centres plus greenfield and brownfield expansions.

Earlier

• Results for April to June 2026: Revenue up 13.4% and profit up 166.7% on a year earlier.

Healthcare Global Enterprises has paid no dividend on the NSE since 1 April 2021, the start of the period we checked.

No. Healthcare Global Enterprises Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 7 August 2026, Healthcare Global Enterprises' management guided: Mid-teens revenue growth from existing centres plus greenfield and brownfield expansions.

“Over the next 2 years, we are looking at a 21-22% EBITDA margin. Over the next 4 to 5 years, we are confident of exceeding the 25% margin level.”Management, on the call for April to June 2026

What management guided

• Consolidated operating margin 21-22% over the next 2 years.
• Consolidated operating margin above 25% over the next 4-5 years.
• Additional operational beds: 65 in FY27, 520 in FY28-FY29 and 230 in FY30; nearly 60% brownfield and three greenfield projects.
• North Bangalore monthly break-even during FY27 and optimal utilization of 60-65% within 3-4 years.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 7 August 2026.

When Healthcare Global Enterprises reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: North Bangalore to hit the stated monthly break-even goal; track clinician ramp-up, insurance empanelments and catchment awareness.

Healthcare Global Enterprises is not on any of our India lists this week.

Healthcare Global Enterprises Ltd earned ₹16.0 Cr of net profit in the Jun 2026 quarter, +166.7% on the same quarter a year earlier. Full-year FY26 profit was ₹23.0 Cr. Over 10 years profit has grown 27.7% a year on average. That is 2.3% of the quarter's revenue. The same quarter a year earlier earned ₹6.0 Cr.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

1 of the last 12 reported quarters were loss-making.

For the full year, FY26 profit was ₹23.0 Cr (−53.1% on the year before).

Why profit moved: revenue changed +13.4% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed −19.1% and revenue +13.7%. Profit is growing slower than sales: rising costs are taking part of the growth.

Healthcare Global Enterprises Ltd reported ₹695 Cr of revenue in the Jun 2026 quarter, +13.4% on the same quarter a year earlier. That is the 11th quarter in a row with growth on the year before. Over 10 years it has grown 15.8% a year on average. The last full year, FY26, came in at ₹2,538 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹2,627 Cr.

FY26 revenue was ₹2,538 Cr, +14.4% on the year before.

Recent pace: the last four quarters grew +13.7% on average, against 15.8% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +13.7%, against +15.2% a year over the last 8 quarters (stabilising); profit over the last 12 months grew −21.4%, against −19.6% a year (stabilising).

Healthcare Global Enterprises Ltd's operating margin was 18.0% in the Jun 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 9.0% and 18.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.0 percentage points on the year while gross margin changed +0.7 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years, 840% of Healthcare Global Enterprises Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹347 Cr of operating cash against ₹23.0 Cr of profit. After ₹258 Cr of spending on assets, ₹89.0 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 840% of profit came in as cash: the cash cycle got 28 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives.

What to look at next: the bigger use of cash is spending on new assets, at 2.4× depreciation over three years. The next section checks what that spending is building.

Healthcare Global Enterprises Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was −93 days in FY26, up from −121 days in FY21. It spent ₹1,539 Cr on assets over the last 3 years. Customers take 60 days to pay, and stock sits for 32 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹2,538 Cr, each day of that cycle ties up about ₹7.0 Cr, so roughly −₹647 Cr is tied up in the business at any time.

FY26: customers took 60 days to pay and stock sat for 32 days, about 1.1 months of sales sitting as stock, for a full cycle of −93 days, longer than FY21's −121.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 32 days. Customers pay about 60 days after that. Suppliers are paid at 185 days. Together that makes the −93-day cycle.

Spending on assets: ₹1,539 Cr over the last 3 years, against ₹629 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹19.0 Cr (FY26): assets paid for that are not earning yet.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

Healthcare Global Enterprises Ltd's P/E is 191.9×, in the middle of its own history: higher than 60% of past readings. Its usual P/E (the middle reading) is 160.9×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.